Related by context. All words. (Click for frequent words.) 76 kidney urologic 75 recurrent glioblastoma multiforme 75 metastatic malignant 75 pancreatic adenocarcinoma 75 polycythemia vera PV 75 histologic subtype 74 epithelial tumors 74 biliary tract cancer 74 thyroid carcinoma 74 prostate carcinoma 74 LHRH receptor positive 74 essential thrombocythemia ET 73 demonstrated antitumor activity 73 urothelial 73 pancreatic prostate 73 colorectal adenoma 73 histological subtype 73 nonmetastatic 73 lymphomas leukemias 73 hypereosinophilic syndrome 73 haematologic 73 relapsed MM 73 CYT# potent vascular disrupting 73 recurrent metastatic 72 fallopian tube cancers 72 colorectal adenocarcinoma 72 gastric adenocarcinoma 72 cisplatin gemcitabine 72 NMIBC 72 epithelial ovarian 72 brivanib 72 cisplatin resistant 72 colorectal carcinoma 72 surgically resected 72 metastatic gastric 72 gastric carcinoma 72 receptor tyrosine kinase inhibitor 72 urothelial carcinoma 72 mucinous 72 metastatic colorectal 72 myeloproliferative diseases 72 breast carcinoma 72 urothelial cancer 72 squamous cell lung cancer 72 myelodysplastic myeloproliferative diseases 72 metastatic GIST 72 hepatoma 72 severe oral mucositis 72 lenalidomide Revlimid R 72 papillary carcinoma 71 leukemia AML 71 Ribavirin causes 71 thymoma 71 hepatocellular carcinomas 71 T1c 71 sarcomatoid 71 K ras mutations 71 hamartomas 71 breast carcinomas 71 syngeneic 71 metastatic bladder 71 AML MDS 71 pulmonary metastases 71 metaplasia 71 leiomyomas 71 novel VDA molecule 71 thalidomide Thalomid 71 acute myeloid 71 metastatic pancreatic 71 Papillary 71 SSc 71 chronic eosinophilic leukemia 71 skeletal metastases 71 renal cell carcinomas 71 gemcitabine Gemzar ® 71 underwent surgical resection 71 recurrent malignant glioma 71 metastatic neuroendocrine tumors 71 Leukemias 71 Soft Tissue Sarcoma 71 epithelioid 71 surgically resectable 71 vinca alkaloid 71 Endometrial 71 histologically confirmed 71 biochemical relapse 71 malignant fibrous histiocytoma 70 transthyretin amyloidosis 70 unresectable tumors 70 INSPIRE Trial Phase III 70 multicentric 70 deep venous thromboses 70 CLL SLL 70 completely resected 70 EGFR HER2 70 MGd 70 localized renal 70 nutlin 3a 70 BRAF V#E 70 pancreatic colon 70 ara C 70 Vidaza ® 70 basal cell carcinoma BCC 70 p# biomarker 70 orally administered inhibitor 70 histologies 70 gastrointestinal stromal tumors GISTs 70 lymphoid malignancies 70 fosbretabulin 70 lymphocytosis 70 radiochemotherapy 70 myelofibrosis polycythemia vera 70 essential thrombocythemia 70 MAGE A3 ASCI 70 bronchogenic carcinoma 70 liver metastasis 70 fibroma 70 carcinoid tumors 70 invasive lobular 70 Chronic lymphocytic leukemia 70 HBeAg negative 70 ANCA associated 70 paragangliomas 70 pheochromocytoma 70 erlotinib Tarceva ® 70 relapsed ALL 70 cutaneous T 70 Adenomas 70 cervical lymph nodes 70 refractory chronic lymphocytic 70 melanoma ovarian 70 Enzastaurin 70 bladder ovarian 70 lung esophageal 70 ovarian pancreatic 70 Hepatocellular Carcinoma HCC 69 bronchoalveolar lavage BAL 69 HepG2 cells 69 esophageal carcinoma 69 underwent resection 69 adenomatous 69 potent inducer 69 FluCAM arm 69 lung pancreatic 69 clinico pathological 69 Pharmacokinetics PK 69 polyposis 69 Hurthle cell 69 complement inhibitor eculizumab 69 osteosarcomas 69 AKT inhibitor 69 Xanafide 69 Sudhir Agrawal D.Phil 69 polycythemia vera essential thrombocythemia 69 familial amyloidotic polyneuropathy FAP 69 mutated K ras 69 HepDirect prodrug 69 visceral metastases 69 hepatorenal syndrome 69 haematopoietic stem cell 69 gefitinib Iressa 69 resectable pancreatic cancer 69 aplastic anemia AA 69 carcinoma HCC 69 myeloproliferative disorders 69 BEXXAR Therapeutic Regimen 69 KRAS oncogene 69 NSCLC tumors 69 Orally administered 69 squamous cell carcinoma SCC 69 prostate cancer CaP 69 FUSILEV enhances 69 tumors GIST 69 hypermethylated 69 systemic anaplastic large 69 refractory NSCLC 69 invasive lobular carcinoma 69 subependymal giant cell 69 estramustine 69 nodal metastasis 69 fallopian tube carcinoma 69 Glioblastoma Multiforme GBM 69 Acute myeloid leukemia 69 humanised monoclonal antibody 69 cell lymphoma CTCL 69 RRM1 69 bronchoalveolar 69 intestinal metaplasia 69 ertapenem 69 adriamycin 69 KRAS mutations occur 69 Sezary syndrome 69 chimeric monoclonal antibody 69 thyroid carcinomas 69 myocardial infarction ventricular fibrillation 69 untreated metastatic melanoma 69 prostate carcinomas 69 parathyroid carcinoma 69 HNSCC 69 Renal Cell Carcinoma RCC 69 gallium nitrate 69 pDC 69 Trichophyton rubrum 69 Upregulation 69 tumor histology 69 treatment naive genotype 69 hyperphenylalaninemia HPA due 69 paraganglioma 69 relapsing remitting MS RRMS 69 recurrent NSCLC 69 recurrent epithelial ovarian 69 Waldenstrom macroglobulinemia 69 PLX STROKE targeting 69 pediatric acute lymphoblastic 69 Immunohistochemical staining 69 pretransplant 69 intraepithelial neoplasia 69 Myelodysplastic Syndrome MDS 69 Cutaneous T 69 cutaneous melanoma 69 advanced hepatocellular carcinoma 69 Intravenous immunoglobulin 69 pancreatic lung 69 TRAIL R1 68 lung carcinomas 68 ovarian carcinoma 68 tumoral 68 clinicopathologic 68 nasopharyngeal carcinoma 68 Diffuse Large B 68 adrenocortical cancer 68 nonmelanoma 68 concurrent chemoradiation 68 non resectable 68 HER2 expression 68 invasive ductal 68 ZACTIMA 68 CC genotype 68 pain palliation 68 neoadjuvant treatment 68 Glioblastoma Multiforme 68 ovarian endometrial 68 neuroendocrine carcinoma 68 osteogenic 68 small lymphocytic lymphoma 68 endometrial hyperplasia 68 HGPIN 68 busulfan 68 Squamous 68 pulmonary metastasis 68 allogeneic HSCT 68 tumorigenicity 68 anthracycline taxane 68 metastatic lymph nodes 68 neutropenia dehydration dyspnea 68 normal karyotype 68 primary hyperparathyroidism 68 Mitomycin C 68 docetaxel Taxotere ® 68 colorectal liver metastases 68 stage IIIb IV 68 ductal carcinomas 68 nonsmall cell lung cancer 68 J. Clin 68 haematopoietic 68 Platinol ® cisplatin 68 BCG refractory 68 castrate resistant 68 huN# DM1 68 cisplatin chemotherapy 68 neoplastic cells 68 metastatic malignant melanoma 68 allogeneic bone marrow 68 Hodgkin lymphoma HL 68 endometrioid 68 tryptase 68 HIV HCV coinfected 68 Hematologic 68 radiotherapy RT 68 HER2 overexpression 68 papillary thyroid carcinoma 68 5alpha reductase 68 PANVAC VF 68 Omacetaxine 68 neoplastic 68 situ LCIS 68 multicenter Phase II 68 operable breast cancer 68 Lymphocytic 68 advanced metastatic renal 68 colorectum 68 histone deacetylase inhibitor 68 vapreotide acetate 68 adrenocortical carcinoma 68 intra abdominal infections 68 cervical lymph node 68 daily subcutaneous injections 68 squamous 68 intravesical therapy 68 intravesical infusion therapy 68 neoplasm 68 hormone refractory metastatic prostate 68 fibrosarcoma 68 antiangiogenic agent 68 adenocarcinomas 68 malignant ascites 68 keloid scarring 68 immunohistochemical staining 68 pharmacologically active isomer 68 alkylating agent 68 including eniluracil ADH 68 COL#A# 68 biologic DMARD 68 neuroendocrine cancers 68 pancreatic neuroendocrine 68 locoregional recurrence 68 benign prostatic hypertrophy BPH 68 allogeneic epidermal 68 paclitaxel cisplatin 68 Toxicities 68 hyperplastic 68 Ph + acute lymphoblastic 68 azacytidine 68 hepatocellular liver 68 dasatinib Sprycel ® 68 refractory colorectal cancer 68 monocytic 68 anastrazole 68 potently inhibited 68 antiretroviral naïve 68 malignant neoplasm 68 protein tyrosine phosphatase 1B 68 BR.# 68 hemorrhagic cystitis 68 CTEPH 68 breast pancreatic 68 prokinetic agent 68 intrahepatic bile duct 68 CTAP# Capsules 68 cervical carcinoma 68 2 methoxyestradiol 68 sorafenib Nexavar 68 huC# DM4 67 Mg Uk 67 R Saizen R 67 mouse xenograft models 67 Parathyroid Hormone 67 lung adenocarcinomas 67 refractory cutaneous T 67 CYP#A# CYP#D# 67 monoclonal antibody conjugated 67 5 fluorouracil leucovorin 67 taxane resistant 67 Gleevec resistant 67 pretreatment serum 67 dacarbazine DTIC 67 Xelox 67 ductal adenocarcinoma 67 VP# [004] 67 cholangiocarcinoma 67 follicular thyroid cancer 67 bullous 67 AA Amyloidosis 67 ß blockers 67 postoperative chemotherapy 67 bronchoalveolar lavage fluid 67 TIMP 67 Cloretazine R 67 sodium thiosulfate STS 67 pancreatic carcinoma 67 advanced adenoma 67 Fludara ® 67 underlying vasculopathy 67 antiproliferative effects 67 benign neoplasms 67 BRAF gene mutations 67 radiolabeled TM# 67 thoracoscopic lobectomy 67 chronic thromboembolic pulmonary 67 metastatic renal 67 Adjuvant chemotherapy 67 tumor necrosis 67 relapsed leukemia 67 gastric cardia 67 bladder carcinoma 67 KRAS mutant 67 Angiotensin Converting Enzyme 67 ENMD # 67 interstitial fibrosis 67 malignant prostate 67 pamidronate 67 endometrial ovarian 67 chronic myeloid 67 LRP5 67 primary peritoneal 67 bevacizumab Avastin R 67 tumor xenograft models 67 cytoreduction 67 Monocyte 67 renal tumors 67 Cathepsin B 67 carcinoids 67 serous ovarian cancer 67 antiangiogenic therapy 67 inducible nitric oxide synthase 67 histologic findings 67 Darinaparsin 67 anaplastic 67 PAOD 67 Doxil ® 67 colon carcinoma 67 cytogenetic abnormalities 67 haematological 67 pT2 67 flutamide 67 neoplasias 67 atypical hemolytic uremic syndrome 67 galiximab 67 weekly subcutaneous injections 67 imatinib resistant 67 peritoneal carcinomatosis 67 Epstein Barr Virus EBV 67 xenograft models 67 TTR amyloidosis 67 locoregional 67 malignant ovarian 67 leukemia multiple myeloma 67 Acute myelogenous leukemia 67 sarcoma melanoma 67 synovial tissue 67 monoclonal anti 67 resectable 67 pT3 67 vitamin B# folic acid 67 esophageal gastric 67 EGFR mutation positive 67 ABCB1 67 evaluating tivozanib 67 nondiabetic patients 67 Chronic lymphocytic leukemia CLL 67 prospective multicenter study 67 metastatic adenocarcinoma 67 HER2 positive metastatic breast 67 transarterial 67 pleomorphic 67 non resectable metastatic 67 Histological 67 renal pelvis 67 transitional cell carcinoma 67 anthracyclines taxanes 67 thymectomy 67 thymic carcinoma 67 androgen receptor AR 67 medically inoperable 67 Bayer HealthCare Onyx Pharmaceuticals 67 abnormal p# 67 alkylating 67 accumulate preferentially 67 chemo immunotherapy 67 basal cell skin 67 lymphoid tumors 67 mTOR inhibitors 67 receiving chemoradiation therapy 67 aplasia 67 Elevated serum 67 dasatinib Sprycel 67 interleukin IL -# 67 CTAP# 67 metastatic colorectal carcinoma 67 plasma pharmacokinetics 67 Subgroup analysis 67 desmoplastic 67 novel emulsion formulation 67 endothelial activation 67 Atypical Hemolytic Uremic Syndrome 67 GSTP1 67 GSTT1 67 basal cell nevus syndrome 67 myeloproliferative neoplasms 67 pancreatic islet cell 67 lymphoid cells 67 FGFR2 67 IMiDs ® compound 67 TNF blocker therapy 67 seminoma 67 Mg Usa 67 hematologic toxicity 67 mycosis fungoides 67 aminotransferase 67 potent antiproliferative 67 decompensated liver disease 67 cholelithiasis 67 prostate adenocarcinoma 67 transplantation HCT 67 Synovial 67 fibrin deposition 67 bronchoalveolar lavage 67 elevated transaminases 67 MTHFR 67 Relapsed Refractory 67 gastrointestinal stromal tumor 67 c KIT 67 malignant lymphomas 67 R lenalidomide 67 lymphoproliferative disorders 67 ZOLINZA 67 hematopoietic cancers 67 acute GvHD 67 HCV replicon 67 neoadjuvant 67 ipsilateral breast 67 stage IIIB 67 immunocompetent 67 esophagogastric junction 67 denileukin diftitox 67 Squamous cell 67 Estrogen Receptor 67 BRIM2 67 achieved CCyR 67 hypophosphatemia 67 chromosomal mutations 67 gemcitabine carboplatin 67 HeFH 67 Kit CD# positive 67 colorectal gastric 67 leucopenia 67 TO AVOID PREGNANCY WHILE 67 MELAS 67 retinoic acid receptor 67 microsphere therapy 67 curative resection 67 Basal cell 67 mesangial 67 nasopharyngeal cancer 67 Naive Patients 67 colorectal neoplasms 67 granulomatous 67 GRNOPC1 contains 67 depsipeptide 67 murine model 67 sunitinib Sutent 67 nonalcoholic steatohepatitis NASH 67 Tarceva TM 67 lactate dehydrogenase LDH 67 refractory acute myeloid 67 TMPRSS2 ERG fusion 66 GPC5 66 AAG geldanamycin analog 66 hepatic metastases 66 trastuzumab Herceptin ® 66 tumor lysis syndrome 66 myelomas 66 superficial basal cell carcinoma 66 malignant pleural mesothelioma 66 flavopiridol 66 Vidaza azacitidine 66 astrocytoma 66 clinicopathological 66 infused intravenously 66 prostanoid 66 Metastatic breast cancer 66 prostate cancer PCa 66 bladder prostate 66 Teriflunomide 66 Ibritumomab Tiuxetan 66 rs# [004] 66 ADPKD 66 Pemetrexed 66 samalizumab 66 colorectal pancreatic 66 Histologically 66 Phase #b/#a clinical 66 paclitaxel poliglumex 66 BARACLUDE ® 66 Folfox 66 Polymorphisms 66 tyrosine kinase inhibitors TKIs 66 cytogenic 66 trial evaluating PRX# 66 hormone receptor negative 66 PI3K/Akt pathway inhibitor 66 erythropoietic 66 BRCA1 BRCA2 66 somatostatin analog 66 chemotherapy cisplatin 66 leiomyoma 66 biliary tract 66 GISTs 66 immunohistochemical 66 differentiated thyroid 66 advanced medullary thyroid 66 malignant lymphoma 66 xenograft tumors 66 inverse agonist 66 mediated inhibition 66 AZT zidovudine Retrovir 66 lung cancer NSCLC 66 catheter occlusion 66 Surgical resection 66 Radical prostatectomy 66 heavily pretreated 66 included exfoliative dermatitis 66 platelet dysfunction 66 heparanase 66 myxoid 66 gastrointestinal stromal 66 distant metastasis 66 intracranial hemorrhage ICH 66 Proxinium TM 66 microtubule inhibitor 66 Sapacitabine 66 refractory indolent non 66 osteoblastic 66 stage IIIA 66 pituitary adenomas 66 metachronous 66 refractory metastatic 66 multiple myeloma MM 66 follicular lymphoma FL 66 MALT lymphoma 66 intradermal injections 66 histologically proven 66 PSMA ADC 66 mononuclear 66 adjuvant radiotherapy 66 GVAX ® 66 IL# PE#QQR 66 transplantation HSCT 66 antitumor effect 66 iobenguane 66 endocervical 66 total thyroidectomy 66 mucosal inflammation 66 VNP#M 66 diagnostic biomarker 66 non splenectomized 66 treat benign prostatic 66 papillary RCC 66 gastroduodenal 66 endobronchial 66 Fibroblast 66 chemoresistant 66 TRAIL R2 66 bladder tumors 66 precursor lesions 66 ExTRACT TIMI 66 indinavir Crixivan 66 cytopenias 66 candidemia 66 hyperoxaluria 66 microsatellite instability 66 Tumor Response 66 Immunotherapeutic 66 PPAR gamma agonist 66 squamous carcinoma 66 chemoradiation therapy 66 anthracycline chemotherapy 66 PNP inhibitor 66 squamous histology 66 Phase 1b clinical trials 66 chronic idiopathic thrombocytopenic purpura 66 Mesenchymal 66 cis retinoic acid 66 liver colon rectal 66 Moraxella catarrhalis 66 palliative radiotherapy 66 PNET 66 treatment naïve genotype 66 Infusion Reactions Severe 66 vinorelbine tartrate 66 Adenoviral 66 Antigen Specific 66 ErbB2 positive 66 carcinoid tumor 66 cyclin dependent kinase inhibitor 66 Heterozygous Familial Hypercholesterolemia 66 CRp 66 FOLFOX6 chemotherapy regimen 66 Philadelphia Chromosome Positive 66 adipogenic 66 acute leukemias 66 targeted antifolate 66 induces apoptosis 66 haematologic malignancies 66 LAB CGRP 66 severe hypersensitivity reactions 66 Amgen Neulasta ® 66 node metastases 66 sinonasal 66 Triapine R 66 PROSTVAC VF 66 ADVEXIN therapy 66 INCB# [003] 66 humanised antibody 66 BRAF V#E mutation 66 smoldering myeloma 66 Metastases 66 cytologically confirmed 66 endometriosis ovarian cysts 66 histologic examination 66 pouchitis 66 Adenocarcinoma 66 esophagogastric 66 antisense inhibitors 66 proliferative disorders 66 reduce serum phosphate 66 Fas ligand 66 histopathologic examination 66 bevacizumab Avastin ® 66 irinotecan doxorubicin oxaliplatin paclitaxel 66 Myelodysplastic syndromes MDS 66 selective modulator 66 pathophysiological effects 66 superficial bladder cancer 66 allogeneic stem cell 66 thrombocytopenic 66 abacavir Ziagen 66 fluconazole resistant 66 Hematopoietic 66 refractory ovarian cancer 66 relapsed Acute Myeloid 66 Hypotension 66 deCODE BreastCancer 66 Gorlin syndrome 66 unstable angina UA 66 pancreatic ductal 66 Stage IIIb 66 ALK inhibitors 66 invasive carcinomas 66 liposomal formulation 66 polypoid 66 5 Fluorouracil 66 paricalcitol 66 neoadjuvant therapy 66 colorectal lung 66 anti angiogenic agents 66 Anthracycline 66 Basal Cell 66 ovarian breast 66 Allogeneic 66 oligodendrogliomas 66 intestinal polyps 66 HGS ETR1 mapatumumab 66 selective phosphodiesterase 66 genotypic resistance 66 ® lenalidomide 66 fusion enhancers 66 extrahepatic 66 assay detects 66 cetuximab Erbitux R 66 idiopathic membranous nephropathy 66 Hsp# Inhibitor 66 cell lymphoma ALCL 66 targeted radiotherapeutic 66 Lenocta 66 Histopathological 66 pancreatic endocrine 66 psoriatic arthritis PsA 66 Amrubicin 66 Amgen Neulasta R 66 topically administered 66 Gliadel Wafer 66 hepatic cirrhosis 66 neoplastic lesions 66 interferon IFN 66 portal vein thrombosis 66 alvespimycin 66 acid phosphatase PAP 66 Hypertrophy 66 carmustine 66 neurological manifestations 66 Histologic 66 mitoxantrone plus 66 ERBB2 66 histone deacetylase HDAC inhibitor 66 Glucocorticoids 66 riociguat 66 BRCA deficient 66 gastrointestinal stromal tumor GIST 66 cystic fibrosis chronic pancreatitis 66 Vicinium TM 66 doxorubicin cyclophosphamide 66 number NCT# ClinicalTrials.gov 66 cyclophosphamide methotrexate 66 liposomal doxorubicin 66 ALN HPN 66 oral squamous cell 66 hepatocellular carcinoma HCC 66 docetaxel Taxotere R 66 NPM1 mutations 66 Patients Treated With 66 replicon 66 allogeneic hematopoietic stem cell 66 forodesine 66 GBM tumors 66 Systemic lupus erythematosus 66 systemic ALCL 66 anaphylactic reactions bronchospasm 65 monogenic 65 methicillin susceptible Staphylococcus aureus 65 plasmid encoding 65 localized prostate 65 idiopathic PAH 65 Myelodysplastic Syndrome 65 oral picoplatin 65 mesenteric 65 pathologic diagnosis 65 Clusterin 65 interstitial brachytherapy 65 Proellex TM 65 targeted nucleotide prodrug 65 leukemias lymphomas 65 metastatic relapsed 65 hematological diseases 65 peritoneal cancer 65 Refractory Hodgkin Lymphoma 65 Immunohistochemical analysis 65 eccrine 65 VEGFR2 inhibitor 65 HSCT 65 dyslipidemia hypertension diabetes 65 undergone radical prostatectomy 65 5 FU leucovorin 65 T#I [002] 65 fulminant hepatic failure 65 JAK2 V#F 65 immunomodulatory therapy 65 promoter methylation 65 CALGB # [002] 65 prostate ovarian 65 alpha1 antitrypsin deficiency 65 deCODE ProstateCancer TM 65 TMPRSS2 ERG 65 LHRH agonists 65 exocrine 65 pancreatic gastric 65 hypervascular tumors 65 bexarotene 65 bronchial epithelial cells 65 glomerulonephritis 65 constitutively expressed 65 comparator arm 65 antimitotic 65 castration resistant hormone refractory 65 Medullary thyroid cancer 65 vaginal candidiasis 65 redox active 65 IDH1 mutation 65 ERK signaling 65 pyelonephritis 65 Kahalalide F 65 Seliciclib 65 pegylated liposomal doxorubicin 65 Cloretazine 65 uricase 65 myeloproliferative 65 histologic subtypes 65 vulvar intraepithelial neoplasia 65 hyper IgE syndrome 65 sorafenib tablets 65 serum leptin 65 lexidronam injection 65 Glioma 65 grade squamous intraepithelial 65 antibody MAb 65 Evoltra ® 65 FLT3 ITD 65 Vascular Disrupting Agent 65 β blockers 65 Panzem NCD 65 MYLOTARG 65 selectively inhibited 65 patientswith 65 pancytopenia 65 ductal lobular 65 pancreas esophagus 65 G CSFs 65 Bezielle 65 chemo resistant 65 receiving XGEVA 65 factor HGF 65 TIMP 1 65 intravenous bisphosphonates 65 Fluorouracil 65 thyrotoxicosis 65 docetaxel chemotherapy 65 Cell Lymphoma CTCL 65 pleural mesothelioma 65 astrocytomas 65 imatinib Gleevec 65 Multiple Myeloma MM 65 basal cell carcinoma squamous 65 grade cervical intraepithelial 65 tiuxetan 65 recurrent glioblastoma multiforme GBM 65 recurrent squamous cell carcinoma 65 lesional 65 metastatic hormone refractory 65 SOD2 gene 65 nilotinib Tasigna ® 65 premalignant 65 SCCHN 65 eribulin mesylate 65 HMG CoA reductase inhibitors 65 B Cell Lymphoma 65 upregulates 65 HDAC Inhibitor 65 gemcitabine Gemzar 65 de novo AML 65 leukemia CLL 65 renal carcinoma 65 Antitumor Activity 65 cell acute lymphoblastic 65 urate oxidase 65 androgen independent 65 hamartoma 65 acute humoral rejection 65 PKC# 65 Stage IIB 65 immune globulin intravenous 65 preoperative chemotherapy 65 mediastinitis 65 hematological relapse 65 ovarian carcinomas 65 lamivudine resistant 65 radiotherapeutic 65 pan HDAC inhibitor 65 aurora kinase 65 pediatric malignancies 65 thetreatment 65 #I TM# 65 neurologic progression 65 pheochromocytomas 65 mg q#h 65 adenomatous polyps 65 TET2 65 soft tissue sarcomas 65 hip osteonecrosis avascular 65 taxane chemotherapy 65 B7 H3 65 pathological hallmark 65 Cholangiocarcinoma 65 microbiologically evaluable 65 NS5B polymerase 65 wedge resection 65 steroid refractory 65 autologous SCT 65 receiving immunosuppressive therapy 65 ThermoDox R 65 anaplastic astrocytoma AA 65 telomerase inhibition 65 MCSP respectively 65 CIN2 + 65 IgA deficiency 65 cortisol synthesis 65 alkylating agents 65 T1a 65 Parathyroid hormone 65 clinicopathological features 65 Randomized Phase II 65 Carcinoid tumors 65 cancer mCRC 65 Western blotting 65 hematopoietic cell 65 trans retinoic acid 65 refractory chronic myeloid 65 tumor regressions 65 receptor inhibitor 65 Dacogen decitabine 65 Neulasta ® 65 severe neutropenia 65 ERK1 2 65 malignant neoplasms 65 carcinoid 65 Unstable Angina 65 choroidal neovascularization CNV 65 baseline LDH 65 myeloproliferative disorder 65 lung ovary 65 HER2 amplified 65 Shows Promise Against 65 Chronic Lymphocytic Leukemia CLL 65 rFVIIa 65 antiphospholipid antibodies 65 oral cavity pharynx 65 IgG1 monoclonal antibody 65 adjuvant cisplatin 65 ovarian lung 65 MPGN 65 FDG PET imaging 65 missense mutations 65 intraductal 65 supratentorial 65 Aplidin 65 Renal impairment 65 alefacept 65 leukocytosis 65 acadesine 65 Epigenomics proprietary